Skip to main content

Table 4 Changes in choroidal thickness during ranibizumab treatment according to neovascularization type

From: Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration

   Baseline 3 months P value* 6 months P value*
Type 2 Subfoveal CT (μm) 238.7 ± 75.8 223.4 ± 72.4 <0.001 224.0 ± 68.5 0.002
(n = 35) Peripapillary CT (μm)
 Mean 157.3 ± 45.1 153.3 ± 43.1 0.154 153.4 ± 42.6 0.163
 Superior 168.8 ± 47.9 165.6 ± 46.3 0.266 165.9 ± 45.3 0.313
 Nasal 155.9 ± 43.7 154.1 ± 43.5 0.511 153.2 ± 42.4 0.340
 Inferior 131.7 ± 39.8 129.2 ± 38.1 0.285 129.9 ± 38.3 0.456
 Temporal 172.5 ± 53.6 164.4 ± 49.4 0.011 164.5 ± 49.2 0.010
Type 3 Subfoveal CT (μm) 145.0 (102.8, 171.2) 124.0 (89.5, 175.8) N/A 117.0 (83.4, 182.5) N/A
(n = 4) Peripapillary CT (μm)
 Mean 112.6 (89.3, 150.8) 117.0 (80.0, 152.5) N/A 117.0 (83.8, 182.5) N/A
 Superior 125.0 (82.5, 193.8) 129.0 (72.8, 194.3) N/A 131.0 (75.0, 195.3) N/A
 Nasal 132.5 (98.5, 156.0) 129.5 (91.0, 167.3) N/A 128.0 (87.5, 173.0) N/A
 Inferior 88.5 (83.0, 93.3) 84.5 (77.8, 104.0) N/A 84.5 (77.8, 110.0) N/A
 Temporal 112.5 (84.0, 161.3) 116.5 (71.5, 160.0) N/A 117.0 (71.3, 162.8) N/A
  1. Continuous variables are expressed as mean ± standard deviation or median (interquartile range)
  2. *Comparison of parameters in each AMD group visit; P value was based on paired t-test
  3. CT choroidal thickness, N/A not applicable